TY - STD TI - The management of lower urinary tract symptoms in men. Available at: https://www.nice.org.uk/guidance/cg97/chapter/1-recommendations/. Accessed 5 July 2016. UR - https://www.nice.org.uk/guidance/cg97/chapter/1-recommendations ID - ref1 ER - TY - STD TI - Management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatis Obstruction (BPO). Available at: http://uroweb.org/wp-content/uploads/Non-Neurogenic-Male-LUTS_2705.pdf. Accessed 16 Sept 2016. UR - http://uroweb.org/wp-content/uploads/Non-Neurogenic-Male-LUTS_2705.pdf ID - ref2 ER - TY - JOUR AU - Chapple, C. R. AU - Drake, M. J. AU - Van Kerrebroeck, P. AU - Cardozo, L. AU - Drogendijk, T. AU - Klaver, M. AU - Van Charldorp, K. AU - Hakimi, Z. AU - Compion, G. PY - 2014 DA - 2014// TI - Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms JO - BJU Int VL - 113 UR - https://doi.org/10.1111/bju.12555 DO - 10.1111/bju.12555 ID - Chapple2014 ER - TY - JOUR AU - Agarwal, A. AU - Eryuzlu, L. N. AU - Cartwright, R. AU - Thorlund, K. AU - Tammela, T. L. AU - Guyatt, G. H. AU - Auvinen, A. AU - Tikkinen, K. A. PY - 2014 DA - 2014// TI - What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women JO - Eur Urol VL - 65 UR - https://doi.org/10.1016/j.eururo.2014.01.019 DO - 10.1016/j.eururo.2014.01.019 ID - Agarwal2014 ER - TY - JOUR AU - Speakman, M. J. PY - 2008 DA - 2008// TI - Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? JO - Eur Urol Suppl VL - 7 UR - https://doi.org/10.1016/j.eursup.2008.08.003 DO - 10.1016/j.eursup.2008.08.003 ID - Speakman2008 ER - TY - JOUR AU - Cindolo, L. AU - Pirozzi, L. AU - Fanizza, C. AU - Romero, M. AU - Sountoulides, P. AU - Roehrborn, C. G. AU - Mirone, V. AU - Schips, L. PY - 2014 DA - 2014// TI - Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men JO - Int Urol Nephrol VL - 46 UR - https://doi.org/10.1007/s11255-013-0587-8 DO - 10.1007/s11255-013-0587-8 ID - Cindolo2014 ER - TY - JOUR AU - Kaplan, S. A. AU - McCammon, K. AU - Fincher, R. AU - Fakhoury, A. AU - He, W. PY - 2009 DA - 2009// TI - Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency JO - J Urol VL - 182 UR - https://doi.org/10.1016/j.juro.2009.08.023 DO - 10.1016/j.juro.2009.08.023 ID - Kaplan2009 ER - TY - JOUR AU - Lee, K. S. AU - Choo, M. S. AU - Kim, D. Y. AU - Kim, J. C. AU - Kim, H. J. AU - Min, K. S. AU - Lee, J. B. AU - Jeong, H. J. AU - Lee, T. AU - Park, W. H. PY - 2005 DA - 2005// TI - Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study JO - J Urol VL - 174 UR - https://doi.org/10.1097/01.ju.0000173630.94559.fd DO - 10.1097/01.ju.0000173630.94559.fd ID - Lee2005 ER - TY - JOUR AU - Chapple, C. AU - Herschorn, S. AU - Abrams, P. AU - Sun, F. AU - Brodsky, M. AU - Guan, Z. PY - 2009 DA - 2009// TI - Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers JO - Eur Urol VL - 56 UR - https://doi.org/10.1016/j.eururo.2008.11.026 DO - 10.1016/j.eururo.2008.11.026 ID - Chapple2009 ER - TY - JOUR AU - Kaplan, S. A. AU - Roehrborn, C. G. AU - Rovner, E. S. AU - Carlsson, M. AU - Bavendam, T. AU - Guan, Z. PY - 2006 DA - 2006// TI - Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial JO - JAMA VL - 296 UR - https://doi.org/10.1001/jama.296.19.2319 DO - 10.1001/jama.296.19.2319 ID - Kaplan2006 ER - TY - JOUR AU - Kerrebroeck, P. AU - Chapple, C. AU - Drogendijk, T. AU - Klaver, M. AU - Sokol, R. AU - Speakman, M. AU - Traudtner, K. AU - Drake, M. J. PY - 2013 DA - 2013// TI - Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial JO - Eur Urol VL - 64 UR - https://doi.org/10.1016/j.eururo.2013.07.034 DO - 10.1016/j.eururo.2013.07.034 ID - Kerrebroeck2013 ER - TY - STD TI - European Medicines Committee: Summary of product characteristics for Vesomni 6 mg/0.4 mg modified release tablets. Available at: https://www.medicines.org.uk/emc/medicine/28535/. Accessed 27 Sept 2016. UR - https://www.medicines.org.uk/emc/medicine/28535 ID - ref12 ER - TY - STD TI - Public Assessment Report for Vesomni 6 mg/0.4 mg modified-release tablets. http://db.cbg-meb.nl/Pars/h111622.pdf/. Accessed 7 May 2017. UR - http://db.cbg-meb.nl/Pars/h111622.pdf ID - ref13 ER - TY - STD TI - GlaxoSmithKline UK: European Medicines Committee. Summary of product characteristics for Combodart 0.5 mg/0.4 mg hard capsules. Available at: https://www.medicines.org.uk/emc/medicine/22943. Accessed 8 Nov 2016. UR - https://www.medicines.org.uk/emc/medicine/22943 ID - ref14 ER - TY - JOUR AU - Cramer, J. A. AU - Roy, A. AU - Burrell, A. AU - Fairchild, C. J. AU - Fuldeore, M. J. AU - Ollendorf, D. A. AU - Wong, P. K. PY - 2008 DA - 2008// TI - Medication compliance and persistence: terminology and definitions JO - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research VL - 11 UR - https://doi.org/10.1111/j.1524-4733.2007.00213.x DO - 10.1111/j.1524-4733.2007.00213.x ID - Cramer2008 ER - TY - JOUR AU - Hakimi, Z. AU - Johnson, M. AU - Nazir, J. AU - Blak, B. AU - Odeyemi, I. A. PY - 2015 DA - 2015// TI - Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data JO - Curr Med Res Opin VL - 31 UR - https://doi.org/10.1185/03007995.2014.968704 DO - 10.1185/03007995.2014.968704 ID - Hakimi2015 ER - TY - JOUR AU - Koh, J. S. AU - Cho, K. J. AU - Kim, H. S. AU - Kim, J. C. PY - 2014 DA - 2014// TI - Twelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia JO - Int J Clin Pract VL - 68 UR - https://doi.org/10.1111/ijcp.12241 DO - 10.1111/ijcp.12241 ID - Koh2014 ER - TY - JOUR AU - Brixner, D. I. AU - Jackson, K. C. PY - 2008 DA - 2008// TI - 2nd, Sheng X, Nelson RE, Keskinaslan A: Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations JO - Curr Med Res Opin VL - 24 UR - https://doi.org/10.1185/03007990802319364 DO - 10.1185/03007990802319364 ID - Brixner2008 ER - TY - JOUR AU - Cindolo, L. AU - Pirozzi, L. AU - Sountoulides, P. AU - Fanizza, C. AU - Romero, M. AU - Castellan, P. AU - Antonelli, A. AU - Simeone, C. AU - Tubaro, A. AU - Nunzio, C. PY - 2015 DA - 2015// TI - Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy? JO - BMC Urol VL - 15 UR - https://doi.org/10.1186/s12894-015-0090-x DO - 10.1186/s12894-015-0090-x ID - Cindolo2015 ER - TY - STD TI - Gottwald-Hostalek U, Sun N, Barho C, Hildemann S. Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine. Clinical pharmacology in drug development. 2017;6(1):9–18. ID - ref20 ER - TY - JOUR AU - Hatalova, K. AU - Pella, D. AU - Sidlo, R. AU - Hatala, R. PY - 2016 DA - 2016// TI - Switching from a Free Association of Perindopril/Amlodipine to a Fixed-Dose Combination: Increased Antihypertensive Efficacy and Tolerability JO - Clin Drug Investig VL - 36 UR - https://doi.org/10.1007/s40261-016-0404-0 DO - 10.1007/s40261-016-0404-0 ID - Hatalova2016 ER - TY - JOUR AU - Drake, M. J. AU - Chapple, C. AU - Sokol, R. AU - Oelke, M. AU - Traudtner, K. AU - Klaver, M. AU - Drogendijk, T. AU - Van Kerrebroeck, P. PY - 2015 DA - 2015// TI - Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension JO - Eur Urol VL - 67 UR - https://doi.org/10.1016/j.eururo.2014.07.013 DO - 10.1016/j.eururo.2014.07.013 ID - Drake2015 ER - TY - JOUR AU - Roehrborn, C. G. AU - Oyarzabal Perez, I. AU - Roos, E. P. AU - Calomfirescu, N. AU - Brotherton, B. AU - Wang, F. AU - Palacios, J. M. AU - Vasylyev, A. AU - Manyak, M. J. PY - 2015 DA - 2015// TI - Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart((R)) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results JO - BJU Int VL - 116 UR - https://doi.org/10.1111/bju.13033 DO - 10.1111/bju.13033 ID - Roehrborn2015 ER - TY - JOUR AU - Wagg, A. AU - Compion, G. AU - Fahey, A. AU - Siddiqui, E. PY - 2012 DA - 2012// TI - Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience JO - BJU Int VL - 110 UR - https://doi.org/10.1111/j.1464-410X.2012.11023.x DO - 10.1111/j.1464-410X.2012.11023.x ID - Wagg2012 ER - TY - JOUR AU - Haab, F. AU - Cardozo, L. AU - Chapple, C. AU - Ridder, A. M. PY - 2005 DA - 2005// TI - Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome JO - Eur Urol VL - 47 UR - https://doi.org/10.1016/j.eururo.2004.11.004 DO - 10.1016/j.eururo.2004.11.004 ID - Haab2005 ER - TY - STD TI - Kelleher C, Aballea S, Maman K, Nazir J, Hakimi Z, Chambers C, Odeyemi IA: Comparative Efficacy And Tolerability Of Solifenacin 5mg Versus Oral Antimuscarinic Agents In Overactive Bladder (Oab): A Systematic Literature Review (Slr) And Mixed Treatment Comparison (Mtc). Value in Health. 2014;17(7):A466. ID - ref26 ER - TY - JOUR AU - Chancellor, M. B. AU - Zinner, N. AU - Whitmore, K. AU - Kobashi, K. AU - Snyder, J. A. AU - Siami, P. AU - Karram, M. AU - Laramee, C. AU - Capo, J. P. AU - Seifeldin, R. PY - 2008 DA - 2008// TI - Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study JO - Clin Ther VL - 30 UR - https://doi.org/10.1016/j.clinthera.2008.10.011 DO - 10.1016/j.clinthera.2008.10.011 ID - Chancellor2008 ER - TY - JOUR AU - Toglia, M. R. AU - Serels, S. R. AU - Laramee, C. AU - Karram, M. M. AU - Nandy, I. M. AU - Andoh, M. AU - Seifeldin, R. AU - Forero-Schwanhaeuser, S. PY - 2009 DA - 2009// TI - Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial JO - Postgrad Med VL - 121 UR - https://doi.org/10.3810/pgm.2009.09.2062 DO - 10.3810/pgm.2009.09.2062 ID - Toglia2009 ER - TY - JOUR AU - Benner, J. S. AU - Nichol, M. B. AU - Rovner, E. S. AU - Jumadilova, Z. AU - Alvir, J. AU - Hussein, M. AU - Fanning, K. AU - Trocio, J. N. AU - Brubaker, L. PY - 2010 DA - 2010// TI - Patient-reported reasons for discontinuing overactive bladder medication JO - BJU Int VL - 105 UR - https://doi.org/10.1111/j.1464-410X.2009.09036.x DO - 10.1111/j.1464-410X.2009.09036.x ID - Benner2010 ER - TY - STD TI - Tran AM, Sand PK, Seitz MJ, Gafni-Kane A, Zhou Y, Botros SM: Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome? Int Urogynecology J. 2016. 2017;28(3):409–15. ID - ref30 ER - TY - BOOK PY - 2017 DA - 2017// TI - Analysis of shopping behaviour between 11/2014 and 10/2014, conducted by Netherlands IMS ID - ref31 ER - TY - STD TI - Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Eur Urol. 2017;S0302-2838(17):30062–3 (epub ahead of print). ID - ref32 ER - TY - STD TI - Wagg A, Franks B, Ramos B, Berner T: Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada. Can Urol Assoc J. 2015;9(9–10):343–50. ID - ref33 ER - TY - JOUR AU - Touchette, D. AU - Shapiro, N. PY - 2008 DA - 2008// TI - Medication Compliance, Adherence, and Persistence: Current Status of Behavioral and Educational Interventions to Improve Outcomes JO - J Manag Care Pharm VL - 14 ID - Touchette2008 ER - TY - JOUR AU - Shingler, S. L. AU - Bennett, B. M. AU - Cramer, J. A. AU - Towse, A. AU - Twelves, C. AU - Lloyd, A. J. PY - 2014 DA - 2014// TI - Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model JO - Curr Med Res Opin VL - 30 UR - https://doi.org/10.1185/03007995.2014.952715 DO - 10.1185/03007995.2014.952715 ID - Shingler2014 ER - TY - STD TI - World Health Organization: ATC/DDD Index 2016. Available at: http://www.whocc.no/atc_ddd_index/. Accessed 8 Nov 2016. UR - http://www.whocc.no/atc_ddd_index ID - ref36 ER -